Integral Health Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Integral Health Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.8M	Buy	700,000 +400,000	+133%	+$6.63M	0.52%	54
2025 Q4	$5.69M	Sell	300,000 -50,000	-14%	-$718K	0.28%	68
2025 Q3	$3.23M	Buy	350,000 +40,000	+13%	+$415K	0.22%	73
2025 Q2	$3.53M	Buy	310,000 +35,000	+13%	+$378K	0.32%	64
2025 Q1	$3.27M	Buy	275,000 +25,000	+10%	+$418K	0.35%	67
2024 Q4	$4.71M	Buy	250,000 +50,000	+25%	+$1.15M	0.4%	64
2024 Q3	$4.49M	Buy	200,000 +50,000	+33%	+$1.13M	0.51%	48
2024 Q2	$3.13M	Buy	+150,000	New	+$2.34M	0.3%	67

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Integral Health Asset Management's NRIX Position: Q1 2026 in Review

Integral Health Asset Management increased its Nurix Therapeutics (NRIX) stake by 133% in Q1 2026, buying an estimated $6.63M and bringing the position to 700,000 shares worth $10.8M. The position accounts for 0.52% of the portfolio, ranked #54.

Integral Health Asset Management first reported a position in NRIX in Q2 2024 and has held it in 8 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Integral Health Asset Management held 700,000 shares of Nurix Therapeutics worth $10.8M as of Q1 2026.
Integral Health Asset Management bought 400,000 Nurix Therapeutics shares in Q1 2026, an estimated $6.63M.
Nurix Therapeutics made up 0.52% of Integral Health Asset Management's portfolio in Q1 2026, its #54 holding.
Integral Health Asset Management first reported a position in Nurix Therapeutics in Q2 2024 and has held it in 8 quarters since.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.